Affordable Access

deepdyve-link
Publisher Website

The role of anthracyclines in small cell lung cancer.

Authors
  • López-González, Ana1
  • Diz, Pilar1
  • Gutierrez, Lourdes1
  • Almagro, Elena1
  • García Palomo, Andrés1
  • Provencio, Mariano1
  • 1 1 Medical Oncology, Hospital Universitario León, Spain ; 2 Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Spain. , (Spain)
Type
Published Article
Journal
Annals of translational medicine
Publication Date
Apr 01, 2013
Volume
1
Issue
1
Pages
5–5
Identifiers
DOI: 10.3978/j.issn.2305-5839.2013.01.05
PMID: 25332950
Source
Medline
Keywords
License
Unknown

Abstract

Small cell lung cancer (SCLC) represents the 15% of the totally of lung cancer. The percentage of cases in women is arising due to the differences in smoking patterns; it occurs almost exclusively in smokers and appears to be most common in heavy smokers. The stage of disease at presentation is the most important prognostic factor in patients with SCLC; for patients with extended stage disease, the median survival is around 10 months, and the five-year survival rate is 1 to 2 percent. The standard regimen for patients with extensive disease is cisplatin based chemotherapy. Second line chemotherapy is generally less effective than the initial treatment but it can provide significant palliation for many patients. We make a review here of the different options of second line chemotherapy and the role of anthracyclines in it.

Report this publication

Statistics

Seen <100 times